5-Amino-1MQ vs Retatrutide

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and depletes the cellular pool of S-adenosyl methionine (SAM), a critical methyl donor. By inhibiting NNMT, 5-Amino-1MQ is proposed to increase intracellular NAD+ levels and SAM availability, thereby enhancing cellular energy metabolism and epigenetic regulation. Research published by Neelakantan et al. The same research group at the University of Texas showed that NNMT expression is upregulated in visceral adipose tissue of obese subjects, suggesting the enzyme plays a direct role in metabolic dysfunction. Unlike GLP-1 receptor agonists that suppress appetite centrally, 5-Amino-1MQ operates at the cellular metabolic level by modulating the NAD+ salvage pathway and methylation balance, offering a mechanistically distinct approach. Compared to NMN or NR supplementation (NAD+ precursors), 5-Amino-1MQ addresses NAD+ depletion at the enzymatic level rather than through precursor loading. Studies also suggest NNMT inhibition may improve insulin sensitivity through modulated SIRT1 activity. Store lyophilized powder at -20C protected from moisture; reconstitute in sterile water. This compound is investigated by metabolic biochemistry laboratories, NAD+ biology researchers, and academic institutions studying the intersection of epigenetics and obesity.

Retatrutide

Retatrutide is a first-in-class triple-agonist peptide that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action involves binding all three receptor systems to modulate appetite signaling, glucose homeostasis, and energy expenditure through complementary metabolic pathways. The glucagon receptor component is believed to contribute additional energy expenditure and hepatic lipid metabolism benefits not seen with GLP-1-only or GIP/GLP-1 dual agonists. Compared to semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual), retatrutide represents an expansion of the incretin-based approach by incorporating glucagon receptor activation, which studies suggest modulates thermogenesis and fat oxidation. For research use, the lyophilized powder should be stored at -20C and reconstituted with bacteriostatic water immediately before use; reconstituted solutions remain stable under refrigeration at 2-8C for up to 28 days. This compound is primarily investigated by academic metabolic research centers, pharmaceutical R&D divisions, and endocrinology laboratories studying multi-receptor agonism as a strategy for metabolic syndrome research.

Frequently Asked Questions